BIOTRONIK announces completion of enrollment in the iliac arm of the BIOFLEX-I Study
LAKE OSWEGO, OR, USA, October 8, 2013 – BIOTRONIK, a manufacturer of cardiovascular technology, announced today that it has completed patient enrollment in the iliac arm of its BIOFLEX-I trial. Under the supervision of national primary investigator Dr. Mark W. Burket, Chief of the Cardiovascular Division at the University of Toledo Medical Center in Toledo, OH, the trial will evaluate the safety and effectiveness of the Astron and Pulsar-18 stents in the treatment of peripheral vascular disease with a view towards gaining FDA approval.
The BIOFLEX-I trial is a prospective, non-randomized, multi-center IDE study consisting of two arms: SFA (superficial femoral artery) and iliac. Alongside ongoing enrollment in the SFA arm, the newly completed iliac arm evaluates the use of the Astron stent in the treatment of common or external iliac artery lesions. Astron is CE-marked and commercially available in over 50 countries worldwide. Astron stents were successfully implanted in 160 patients at 34 centers in the U.S. and Europe, completing enrollment in the iliac arm of the BIOFLEX-I trial.
“When treating disease in the iliac arteries, it’s important to have a variety of tools at your disposal,” commented Dr. Burket. “The Astron stent is an excellent option in the self-expanding category. Its flexibility, ease of deployment, and passive PROBIO coating make it a suitable choice for many patients.”
More information on the BIOFLEX-I clinical study is available at www.clinicaltrials.gov identifier: NCT01319812.
For more information, visit: www.biotronik.com